TY - JOUR
T1 - Biologics for Treatment of Atopic Dermatitis
T2 - Current Status and Future Prospect
AU - Ratchataswan, Thanaporn
AU - Banzon, Tina M.
AU - Thyssen, Jacob P.
AU - Weidinger, Stephan
AU - Guttman-Yassky, Emma
AU - Phipatanakul, Wanda
N1 - Funding Information:
Conflicts of interest: T. Ratchataswan declares no relevant conflicts of interest. T. M. Banzon is supported by T32 AI 007512 from the National Institutes of Health. J. P. Thyssen has been an advisor/investigator/speaker for Regeneron, Sanofi-Genzyme, AbbVie, LEO Pharma, Eli Lilly & Co, and Pfizer. S. Weidinger has received institutional research grants from Sanofi Deutschland GmbH, Leo Pharma, and La Roche Posay; has performed consultancies for Sanofi-Genzyme, Regeneron, LEO Pharma, AbbVie, Pfizer, Eli Lilly, Kymab, and Novartis; has lectured at educational events sponsored by Sanofi Genzyme, Regeneron, LEO Pharma, AbbVie, Novartis, and Galderma; and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. E. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from AbbVie, Almirall, Amgen, AnaptysBio, Asana Biosciences, Boehringer Ingelheim, Celgene, Dermavant, DS Biopharma, Eli Lilly, Galderma, Ichnos Sciences, Innovaderm, Janssen, Kiniska, Kyowa Kirin, Leo Pharma, Novan, Pfizer, Ralexar, Regeneron Pharmaceuticals, Inc, Sienna Biopharma, UCB, and Union Therapeutics; and is a consultant for AbbVie, Aditum Bio, Almirall, Amgen, Asana Biosciences, AstraZeneca, Boehringer-Ingelheim, Cara Therapeutics, Celgene, Concert, DBV, Dermira, DS Biopharma, Eli Lilly, EMD Serono, Escalier, Galderma, Ichnos Sciences, Incyte Kyowa Kirin, Leo Pharma, Mitsubishi Tanabe, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc, Sanofi, Sienna Biopharma, Target PharmaSolutions, and Union Therapeutics. W. Phipatanakul is supported by the grants U01 AI 152033 and K24 AI 106822 from the National Institutes of Health and Allergy Asthma Awareness Initiative, Inc; and reports consultancy fees from Genentech, Novartis, Regeneron, Sanofi, GSK, and Astra Zeneca for therapeutics related to Asthma, outside the submitted work. No funding was received for this work.
Funding Information:
Conflicts of interest: T. Ratchataswan declares no relevant conflicts of interest. T. M. Banzon is supported by T32 AI 007512 from the National Institutes of Health . J. P. Thyssen has been an advisor/investigator/speaker for Regeneron, Sanofi-Genzyme, AbbVie, LEO Pharma, Eli Lilly & Co, and Pfizer. S. Weidinger has received institutional research grants from Sanofi Deutschland GmbH , Leo Pharma , and La Roche Posay ; has performed consultancies for Sanofi-Genzyme, Regeneron, LEO Pharma, AbbVie, Pfizer, Eli Lilly, Kymab, and Novartis; has lectured at educational events sponsored by Sanofi Genzyme , Regeneron , LEO Pharma , AbbVie , Novartis , and Galderma ; and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. E. Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from AbbVie , Almirall , Amgen , AnaptysBio , Asana Biosciences , Boehringer Ingelheim , Celgene , Dermavant , DS Biopharma , Eli Lilly , Galderma , Ichnos Sciences , Innovaderm , Janssen , Kiniska , Kyowa Kirin , Leo Pharma , Novan , Pfizer , Ralexar , Regeneron Pharmaceuticals , Inc, Sienna Biopharma , UCB , and Union Therapeutics ; and is a consultant for AbbVie, Aditum Bio, Almirall, Amgen, Asana Biosciences, AstraZeneca, Boehringer-Ingelheim, Cara Therapeutics, Celgene, Concert, DBV, Dermira, DS Biopharma, Eli Lilly, EMD Serono, Escalier, Galderma, Ichnos Sciences, Incyte Kyowa Kirin, Leo Pharma, Mitsubishi Tanabe, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals, Inc, Sanofi, Sienna Biopharma, Target PharmaSolutions, and Union Therapeutics. W. Phipatanakul is supported by the grants U01 AI 152033 and K24 AI 106822 from the National Institutes of Health and Allergy Asthma Awareness Initiative, Inc; and reports consultancy fees from Genentech, Novartis, Regeneron, Sanofi, GSK, and Astra Zeneca for therapeutics related to Asthma, outside the submitted work.
Publisher Copyright:
© 2020 American Academy of Allergy, Asthma & Immunology
PY - 2021/3
Y1 - 2021/3
N2 - Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intense pruritus and recurrent eczematous lesions that significantly impair quality of life. It is a heterogeneous disease affecting both children and adults. The treatment of moderate-to-severe forms of AD is challenging, as topical corticosteroids are often insufficient to achieve disease control or inappropriate and off-label use of immunosuppressants may have significant undesirable side effects. The development of targeted biologic therapies specifically for AD is thus highly desirable. Dupilumab is the only biologic therapy that is Food and Drug Administration approved for the treatment of moderate-to-severe AD in patients 6 years and older, with consistent long-term efficacy and safety trial data. In this article, we review the mechanisms, safety, and efficacy of dupilumab from recent clinical trials, and we review the current data, mechanism of action, clinical efficacy, and limitations of new biologics currently in phase 2 and 3 clinical trials (lebrikizumab, tralokinumab, nemolizumab, tezepelumab, and ISB 830).
AB - Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intense pruritus and recurrent eczematous lesions that significantly impair quality of life. It is a heterogeneous disease affecting both children and adults. The treatment of moderate-to-severe forms of AD is challenging, as topical corticosteroids are often insufficient to achieve disease control or inappropriate and off-label use of immunosuppressants may have significant undesirable side effects. The development of targeted biologic therapies specifically for AD is thus highly desirable. Dupilumab is the only biologic therapy that is Food and Drug Administration approved for the treatment of moderate-to-severe AD in patients 6 years and older, with consistent long-term efficacy and safety trial data. In this article, we review the mechanisms, safety, and efficacy of dupilumab from recent clinical trials, and we review the current data, mechanism of action, clinical efficacy, and limitations of new biologics currently in phase 2 and 3 clinical trials (lebrikizumab, tralokinumab, nemolizumab, tezepelumab, and ISB 830).
KW - Atopic dermatitis
KW - Biologic therapy
KW - Dupilumab
KW - Eczema
KW - GBR 830
KW - ISB 830
KW - Lebrikizumab
KW - Nemolizumab
KW - Tezepelumab
KW - Tralokinumab
UR - http://www.scopus.com/inward/record.url?scp=85101654431&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.11.034
DO - 10.1016/j.jaip.2020.11.034
M3 - Article
C2 - 33685604
AN - SCOPUS:85101654431
SN - 2213-2198
VL - 9
SP - 1053
EP - 1065
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 3
ER -